Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy

Guerrero, Whitney; Munene, Gitonga; Dickson, Paxton V.; Darby, D.; Davidoff, Andrew M.; Martin, Michael; Glazer, Evan S.; Shibata, David; Deneve, Jeremiah L.

doi:10.21037/jgo.2018.01.02

Cited by 3 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to emphasize that one of the main difficulties in the treatment of DSRCT, due to its adhesive nature, is not achieving optimal surgical debulking, with more than 10% of tumor left. 1,[21][22][23][24][25][26][27] We found optimal surgical debulking to be necessary for local disease control and for establishing better response on adjuvant treatment modalities. Other adjuvant treatment modalities may include hyperthermic intraperitoneal chemotherapy, 21,22 yttrium microsphere, 22 or, as presented in our case, high-dose chemotherapy followed by autologous stem-cell support.…”

Section: Discussionmentioning

confidence: 99%

“…1,[21][22][23][24][25][26][27] We found optimal surgical debulking to be necessary for local disease control and for establishing better response on adjuvant treatment modalities. Other adjuvant treatment modalities may include hyperthermic intraperitoneal chemotherapy, 21,22 yttrium microsphere, 22 or, as presented in our case, high-dose chemotherapy followed by autologous stem-cell support. We demonstrated the efficienty of the treatment modality chosen in this case, which combined primary and secondary surgical debulking, CWS chemotherapy protocol, and boost radiotherapy joined with high-dose chemotherapy followed by autologous stem cell support.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Desmoplastic Small Round Cell Tumor of the Ovary: A Case Report with a New Modality of Treatment and Review of the Literature

Vujić

Mikuš

Matak

et al. 2020

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective Desmoplastic small round cell tumor (DSRCT) is a rare intraabdominal neoplasm that grows along serosal surfaces and is primarily found in young men. To date, only 16 cases of ovarian DSRCT have been previously reported in women in the English literature, and no large population-based studies on this topic exist. Case Report We report the case of a 19-year-old virgo with unremarkable past medical history, initially presented with abdominal fullness. After being treated with the optimal treatment modality (primary and secondary surgical debulking, unique chemotherapy, protocol and adjuvant radiotherapy), the patient has remained without tumor disease for 40 months. Conclusion Although the best therapy for patients with DSRCT has yet to be determined, combining complete surgical resection, adjuvant chemotherapy, and radiotherapy is required to prolong survival and to achieve proper quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Desmoplastic Small Round Cell Tumor of the Ovary: A Case Report with a New Modality of Treatment and Review of the Literature

Vujić

Mikuš

Matak

et al. 2020

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

show abstract

“…Due to the rarity of pediatric peritoneal malignancy and the limited sample size of previous studies, CRS and HIPEC were mainly reported as small case series and few case reports. The role of CRS and HIPEC in children remains controversial ( 3 – 5 ). Hayes-Jordan et al began the first pediatric HIPEC program and reported the largest numbers of pediatric CRS and HIPEC procedures, which demonstrated that patients with DSRCT had longer survival than those with other tumors in children ( 1 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant tumors in children: Initial experience in a single institution

et al. 2023

View full text Add to dashboard Cite

BackgroundPeritoneal malignant tumors in children are rare but commonly associated with disease progression and poor outcome. The successful treatment experience of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in adult peritoneal carcinoma has been applied to pediatric peritoneal malignancy in recent years. However, patients with desmoplastic small round cell tumor (DSRCT) accounted for the majority of patients treated with CRS and HIPEC in previous studies. The role of CRS and HIPEC remains controversial due to the rarity of the disease and the limited sample size of studies. Additionally, the cases using CRS and HIPEC except DSRCT were mainly small case reports with unclear outcomes. We present our experience in the treatment of pediatric peritoneal malignancies using CRS and HIPEC, with more emphasis on the safety, feasibility, and short-term outcome.MethodsA retrospective query from December 2019 to February 2022 identified 19 children with peritoneal malignancies who underwent CRS and HIPEC in our institution. Clinical characteristics, therapies, and outcomes were summarized and analyzed.ResultsThe median age of the patients was 6.4 years (range, 0.7–13.9 years). The histologic types included rhabdomyosarcoma (7), Wilms tumor (2), clear cell sarcoma of the kidney (2), undifferentiated sarcoma (2), immature teratoma (1), peritoneal serous carcinoma (1), malignant rhabdoid of the kidney (1), malignant germ cell tumor (1), neuroblastoma (1), and epithelioid inflammatory myofibroblast sarcoma (1). Seven patients underwent initial operation, and 12 patients received reoperation for tumor recurrence. The median peritoneal carcinomatosis index was 5 (range, 2–21). There were no perioperative deaths or life-threatening complications of CRS and HIPEC. Two patients had grade 3 complications of wound infection and wound dehiscence. With a median follow-up time of 14 months (range, 1.5–31 months), 14 patients were alive, and 5 died of tumor recurrence. Of the 14 patients who were alive, 2 relapsed after CRS and HIPEC and then received radiotherapy and molecular-targeted therapy or chemotherapy.ConclusionsCRS and HIPEC are safe and feasible in children, without increasing serious complications in the peri- and postoperative periods. The complication is acceptable. The short-term outcome shows possible effectiveness in pediatric peritoneal malignant tumors. The long-term effectiveness needs to be verified by additional cases and long-term follow-ups.

show abstract

Optimal oncologic and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy are attainable at a community center

Rog

Lucas

Reiter

et al. 2021

The American Journal of Surgery

View full text Add to dashboard Cite

Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy

Abstract: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.

Cited by 3 publications

References 41 publications

Desmoplastic Small Round Cell Tumor of the Ovary: A Case Report with a New Modality of Treatment and Review of the Literature

Desmoplastic Small Round Cell Tumor of the Ovary: A Case Report with a New Modality of Treatment and Review of the Literature

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant tumors in children: Initial experience in a single institution

Optimal oncologic and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy are attainable at a community center

Contact Info

Product

Resources

About